Biogen : Canada Accepts New Drug Submission For Lecanemab As Treatment For Early Alzheimer's Disease
16/5 05:12
(RTTNews) - Eisai Co., Ltd. and Biogen Inc. (BIIB) said that Health Canada has accepted a New Drug Submission or NDS for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (Aß) protofibril antibody, for the treatment of early Alzheimer's disease wit...